Systemic Bio

Systemic Bio is a wholly owned subsidiary of 3D Systems focused on leveraging advanced bioprinting technologies for pharmaceutical drug discovery and development applications. The company employs 3D Systems' breakthrough Print to Perfusion technology to create highly precise, vascularized organ models using biomaterials and human cells. These proprietary organs-on-chips, known as the h-VIOS (human vascularized integrated organ systems) platform, can be manufactured reproducibly in large quantities and perfused with desired drug compounds to study drug metabolism and effects on healthy or diseased tissue. This approach offers the potential to significantly reduce costs and time required for pharmaceutical companies to bring new drugs to market, and could eventually eliminate the need for animal testing preceding human trials.

Systemic Bio was formed in September 2022 with an initial USD 15 million seed investment from 3D Systems. The company is led by CEO Taci Pereira, who previously served as Vice President and General Manager of Bioprinting at 3D Systems. Systemic Bio's efforts are envisioned to create a biotech revenue stream for 3D Systems approaching USD 100 million annually over the next five years.

In April 2023, Systemic Bio opened a state-of-the-art laboratory in Houston, Texas, featuring a cleanroom for bioprinted hydrogel scaffold manufacturing. This facility enables the sterile and quality-controlled production of h-VIOS chips and plates for use by the company's pharmaceutical partners in drug testing. The h-VIOS platform, composed of vascularized hydrogel scaffolds, enables the survival and function of both healthy and diseased human cells, allowing for more physiological drug delivery and evaluation.